{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:02:25Z","timestamp":1793779345402,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003513","name":"University of Surrey","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003513","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.diabres.2023.110239","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T23:55:56Z","timestamp":1672876556000},"page":"110239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: A meta-analysis"],"prefix":"10.1016","volume":"196","author":[{"given":"Chloe","family":"Charlwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenika","family":"Chudasama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Darling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Logan Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin B.","family":"Whyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2023.110239_b0005","first-page":"1","article-title":"Forxiga (dapagliflozin)","author":"Assessment report","year":"2012","journal-title":"Eur Med Agency"},{"key":"10.1016\/j.diabres.2023.110239_b0010","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2018.01.085","article-title":"SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL","volume":"71","author":"Cavender","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2023.110239_b0015","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2023.110239_b0020","unstructured":"European Medicines Agency; 2021."},{"key":"10.1016\/j.diabres.2023.110239_b0025","unstructured":"Administration UFaD, FDA Approves Treatment for Chronic Kidney Disease; 2021."},{"key":"10.1016\/j.diabres.2023.110239_b0030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.diabres.2023.110239_b0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13300-015-0150-y","article-title":"Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis","volume":"7","author":"Yavin","year":"2016","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2023.110239_b0040","unstructured":"US Food and Drug Administration Invokana (canagliflozin) label (May 2014)."},{"key":"10.1016\/j.diabres.2023.110239_b0045","unstructured":"Risk of Hyperkalaemia with Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus, a Systematic Review and Meta-Analysis. doi: 10.17605\/OSF.IO\/BPN3M, 2021."},{"key":"10.1016\/j.diabres.2023.110239_b0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/157488709788186021","article-title":"A general framework for the evaluation of clinical trial quality","volume":"4","author":"Berger","year":"2009","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.diabres.2023.110239_b0055","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.4, The Cochrane Collaboration; 2020."},{"key":"10.1016\/j.diabres.2023.110239_b0060","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.12273","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone","volume":"16","author":"Forst","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2023.110239_b0065","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13300-013-0030-2","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus","volume":"4","author":"Heise","year":"2013","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2023.110239_b0070","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabres.2023.110239_b0075","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110239_b0080","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110239_b0085","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110239_b0090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110239_b0095","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.diabres.2023.110239_b0100","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2023.110239_b0105","unstructured":"Medical Dictionary for Regulatory Activities - Hyperkalaemia. ICH 2020 Sep 2020;23.1."},{"key":"10.1016\/j.diabres.2023.110239_b0110","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1185\/03007995.2014.919907","article-title":"Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)","volume":"30","author":"Weir","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabres.2023.110239_b0115","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/ckj\/sfaa133","article-title":"Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program","volume":"14","author":"Weir","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.diabres.2023.110239_b0120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110239_b0125","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110239_b0130","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110239_b0135","doi-asserted-by":"crossref","DOI":"10.2337\/db21-14-LB","article-title":"14-LB: finerenone in patients with CKD and T2D by SGLT2i treatment: an analysis of the FIDELIO-DKD study","volume":"70","author":"Rossing","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2023.110239_b0140","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2215\/CJN.08580813","article-title":"Regulation of potassium homeostasis","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:24:06Z","timestamp":1759173846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822723000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":28,"alternative-id":["S0168822723000049"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2023.110239","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2023.110239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110239"}}